Myriad Genetics, Inc. (NASDAQ:MYGN) has been given an average rating of “Hold” by the twelve research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $21.00.

Several equities research analysts have commented on MYGN shares. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Monday, July 17th. J P Morgan Chase & Co reiterated an “underweight” rating and set a $16.00 price objective on shares of Myriad Genetics in a research note on Friday, June 30th. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Cowen and Company reiterated a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a research note on Friday, July 14th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $22.00 price objective on shares of Myriad Genetics in a research note on Friday, July 14th.

In other news, Director John T. Henderson sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the sale, the director now directly owns 52,524 shares in the company, valued at $1,591,477.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.20% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Arizona State Retirement System purchased a new stake in shares of Myriad Genetics in the first quarter valued at approximately $682,000. Bank of New York Mellon Corp grew its position in shares of Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after purchasing an additional 521,146 shares in the last quarter. Frontier Capital Management Co. LLC grew its position in shares of Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock valued at $59,058,000 after purchasing an additional 41,432 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Myriad Genetics by 4.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 698,450 shares of the company’s stock valued at $13,411,000 after purchasing an additional 29,348 shares in the last quarter. Finally, Great West Life Assurance Co. Can grew its position in shares of Myriad Genetics by 958.4% in the first quarter. Great West Life Assurance Co. Can now owns 97,514 shares of the company’s stock valued at $1,870,000 after purchasing an additional 88,301 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/09/myriad-genetics-inc-mygn-receives-consensus-rating-of-hold-from-analysts.html.

Myriad Genetics (MYGN) opened at 32.53 on Friday. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of 101.97 and a beta of 0.26. Myriad Genetics has a 52 week low of $15.15 and a 52 week high of $33.42. The company’s 50-day moving average price is $27.51 and its 200-day moving average price is $22.74.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The company had revenue of $200.50 million during the quarter, compared to analyst estimates of $193.71 million. During the same period in the previous year, the business earned $0.36 EPS. Myriad Genetics’s quarterly revenue was up 7.5% on a year-over-year basis. Equities analysts forecast that Myriad Genetics will post $1.02 earnings per share for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.